ProCE Banner Activity

Role of SGLT2 Inhibitors in Type 2 Diabetes With Chronic Kidney Disease

Slideset Download

A leading expert provides an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes.

Released: July 12, 2022

Expiration: July 11, 2023

No longer available for credit.

Share

Faculty

Jennifer B. Green

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Jennifer B. Green MD: consultant/advisor/speaker: Bayer